Advertisement

PharmacoEconomics & Outcomes News

, Volume 840, Issue 1, pp 26–26 | Cite as

Semaglutide has lowest cost of glycaemic control

Clinical study
  • 2 Downloads

Reference

  1. Hunt B, et al. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Advances in Therapy : 24 Oct 2019. Available from: URL: https://doi.org/10.1007/s12325-019-01125-y

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations